The British are preparing an innovative vaccine for CoVID-19 in the form of slices Microneedle patches are quite a hot trend in medicine, although according to experts, it will be many years before they become popular, due to certain limitations of this platform.

If panic fear of needles prevents you from vaccinating against the coronavirus, then you should be interested in the new solution presented by experts from Swansea University. We are talking about a patch that we stick to the skin like those that help fight nicotine addiction and wear for 24 hours. A working prototype will be presented by April, and although it should not be expected that it will be possible to use it later this year, with a less optimistic variant, we will vaccinate Covid-19 as for the flu, i.e. every year, we will ultimately have a less invasive route of administration.

Because although theoretically we are still dealing with needles, these are so tiny that we will not feel them - each is thinner than a human hair, so it penetrates the skin barrier without causing any discomfort: - They do not penetrate the skin as deeply World Wire classic needles and do not stimulate receptors pain, so they are less painful than a classic injection, explains nanotechnologist Olivia Howells of Swansea University. And what is most interesting in all this, the patch is designed because the user could stick it on himself and monitor the body's response. The latter issue is also very interesting, because it turns out that the patch, in addition to giving the vaccine, also measures inflammation in response to it by monitoring biomarkers in the skin.

The ability to quickly measure vaccine efficacy is a response to an unmet clinical need and will certainly be an innovative approach to vaccine development. The real-time operation of this platform means quick results to quickly contain COVID-19 virus, Dr. Sharma explains. It is also important that the vaccine is to be easy to distribute and cheap to produce, which can help significantly increase the prevalence of administration, also in large poor countries, where classic medical points are difficult to find. Especially that although scientists are currently focusing on the coronavirus, ultimately the solution is also to be used in the case of vaccinations for other diseases: - The low cost of the device will ensure a quick return to work and management of the next waves of Covid-19. Beyond the pandemic, our work could be extended to other infectious diseases as the nature of this platform allows for quick adaptation, they add.